A review of the health-related quality of life and economic impact of Parkinson's disease

Drugs and Aging

Volumn 23, Issue 9, 2006, Pages 693-721

  Dowding, Clare H ^a   Shenton, Claire L ^a   Salek, Sam S ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DYSKINESIA; ECONOMIC ASPECT; EDUCATION PROGRAM; HEALTH EDUCATION; HEALTH SERVICE; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; NEUROSURGERY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RATING SCALE; REVIEW; SEX DIFFERENCE;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 33749564261     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623090-00001     Document Type: Review

References (126)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004 May; 363 (9423): 1783-93
2. Martinez-Martin P. An introduction to the concept of "quality of life in Parkinson's disease". J Neurol 1998 May; 245: S2-6
3. Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med 1995; 41 (10): 1383-94
4. Dolan P. Valuing health-related quality of life: issues and controversies. Pharmacoeconomics 1998; 15 (2): 119-27
5. Damiano AM, Snyder C, Strausser B, et al. A review of health-related quality of life concepts and measures for Parkinson's disease. Qual Life Res 1999; 8 (3): 235-43
6. Marinus J, Ramaker C, van Hilten JJ, et al. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002 Feb; 72 (2): 241-8
7. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease. Pharmacoeconomics 2001; 19 (10): 1013-38
8. Rubenstein LM, deLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19 (7): 729-52
9. Brouwer WBF. Too important to ignore: informal caregivers and other significant others. Pharmacoeconomics 2006; 24 (1): 39-41
10. The EuroQol Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
11. Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D: a generic quality of life measure: is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 67-73
12. Tan LCS, Luo N, Nazri M, et al. Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson's disease patients in Singapore. Parkinsonism Relat Disord 2004; 10 (8): 493-9
13. Jenkinson C, Fitzpatrick R, Peto V. Health-related quality of life measurement in patients with Parkinson's disease. Pharmacoeconomics 1999; 15 (2): 157-65
14. Ali T. Validation of patient-reported outcomes in Parkinson's disease: comparisons of generic and disease-specific health-related quality of life instruments [Ph.D. thesis]. Cardiff: Cardiff University, 2005
15. Longstreth WTJ, Nelson L, Linde M, et al. Utility of the Sickness Impact Profile in Parkinson's disease. J Geriatr Psychiatry Neurol 1992; 5 (3): 142-8
16. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 Health Survey Questionnaire - new outcome measure for primary care. BMJ 1992 Jul 18; 305 (6846): 160-4
17. Hobson JP, Meara RJ. Is the SF-36 Health Survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson's disease? Qual Life Res 1997 Apr; 6 (3): 213-6
18. Jenkinson C, Peto V, Fitzpatrick R, et al. Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the Short-Form Health Survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 1995 Nov; 24 (6): 505-9
19. Hagell P, Whalley D, McKenna SP, et al. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord 2003 Jul; 18 (7): 773-83
20. Karlsen KH, Larsen JP, Tandberg E, et al. Quality of life measurements in patients with Parkinson's disease: a community-based study. Eur J Neurol 1998; 5: 443-50
21. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998 May; 245: S10-S4
22. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997 Sep; 26 (5): 353-7
23. Katsarou Z, Bostantjopoulou S, Peto V, et al. Assessing quality of life in Parkinson's disease: can a short-form questionnaire be useful? Mov Disord 2004; 19 (3): 308-12
24. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life Questionnaire. Age Ageing 1999 Jul; 28 (4): 341-6
25. Serrano-Duenas M, Martinez-Martin P, Vaca-Baquero V. Validation and cross-cultural adjustment of PDQL-questionnaire, Spanish version (Ecuador) (PDQL-EV). Parkinsonism Relat Disord 2004 Oct; 10 (7): 433-7
26. Calne S, Schulzer M, Mak E, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson's Impact Scale (PIMS). Parkinsonism Relat Disord 1996; 2 (2): 55-61
27. Schulzer M, Mak E, Calne SM. The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease. Parkinsonism Relat Disord 2003; 9: 291-4
28. Welsh M, McDermott MP, Holloway RG, et al. Development disand testing of the Parkinson's Disease Quality of Life Scale. Mov Disord 2003; 18 (6): 637-45
29. Karlsen KH, Tandberg E, Arsland D, et al. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000; 69: 584-9
30. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D, editors. Recent developments in Parkinson's disease. Florham Park (NJ): Macmillan Healthcare Information, 1987: 153-63
31. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42
32. Beck A, Ward C, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71
33. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham F, Donaldson I, editors. Third symposium on surgery in Parkinson's disease. Edinburgh: Livingstone, 1969: 152-7
34. Folstein M, Folstein S, McHugh P. Mini-Mental State, a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
35. Lyons RA, Perry HM, Littlepage BNC. Evidence for the validity of the Short-Form-36 Questionnaire (SF-36) in an elderly population. Age Ageing 1994 May; 23 (3): 182-4
36. Kuopio A, Marttila RJ, Helenius H, et al. The quality of life in Parkinson's disease. Mov Disord 2000; 15 (2): 216-23
37. Jenkinson C, Fitzpatrick R, Argyle M. The Nottingham-Health-Profile: an analysis of its sensitivity in differentiating illness groups. Soc Sci Med 1988; 27 (12): 1411-4
38. Karlsen KH, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999 Apr; 66 (4): 431-5
39. Martinez-Martin P, Payo BF. Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. J Neurol 1998 May; 245: S34-S8
40. Bushnell DM, Martin ML. Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res 1999 Jun; 8 (4): 345-50
41. deBoer A, Wijker W, Speelman JD, et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996 Jul; 61 (1): 70-4
42. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998 Nov; 13 (6): 885-94
43. Schrag A, Hovris A, Morley D, et al. Young versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 2003 Nov; 18 (11): 1250-6
44. Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson's disease. Mov Disord 2000 Jan; 15 (1): 132-5
45. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20 (2): 224-30
46. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life. Qual Life Res 2000; 9 (1): 87-100
47. Marras C, Lang A, Krahn M, et al. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004; 19 (1): 22-8
48. Zach M, Friedman A, Slawek J, et al. Quality of life in Polish patients with long-lasting Parkinson's disease. Mov Disord 2004 Jun; 19 (6): 667-72
49. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-12
50. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005 Dec; 12 (12): 956-63
51. Just H, Ostergaard K. Health-related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord 2002 May; 17 (3): 539-45
52. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004 Sep; 19 (9): 997-1005
53. Calne SM. The psychosocial impact of late-stage Parkinson's disease. J Neurosci Nurs 2003 Dec; 35 (6): 306-13
54. Chung TH, Deane KHO, Ghazi-Noori S, et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 2003; 10: 59-65
55. Caap-Ahlgren M, Dehlin O. Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr 2001; 32: 23-33
56. Findley L, Eichhorn T, Janca A, et al. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002 Jan; 17 (1): 60-7
57. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson's disease. J Neurol 2004; 251 Suppl. 6: VI/24-VI/7
58. Behari M, Srivastava AK, Pandey RM. Quality of life in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 221-6
59. Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology 2005 Jun; 64: 2134-5
60. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease: a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord 2005 Nov; 11 (7): 465-8
61. Leentjens AF, Verhey FR, Luijckx GJ, et al. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000 Nov; 15 (6): 1221-4
62. Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 2000 Jul; 15 (7): 644-9
63. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
64. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999 Jan; 28 (1): 35-8
65. Playfer JR. Depression, cognition and quality of life in parkinsonian patients. Age Ageing 1999; 28: 333-4
66. Kanner AM. Should neurologists be trained to recognize and treat comorbid depression of neurologic disorders? Yes. Epilepsy Behav 2005 May; 6 (3): 303-11
67. Lezcano E, Gomez-Esteban JC, Zarranz JJ, et al. Improvement in quality of life in patients with advanced Parkinson's disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol 2004; 11: 451-4
68. Defer GL, Widner H, Marie RM, et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999 Jul; 14 (4): 572-84
69. Hagell P, Crabb L, Pogarell O, et al. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Mov Disord 2000 Mar; 15 (2): 224-9
70. Straits-Troster K, Fields JA, Wilkinson SB, et al. Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. Brain Cogn 2000; 42: 399-416
71. Martinez-Martin P, Valldeoriola F, Molinuevo JL, et al. Pallidotomy and quality of life in patients with Parkinson's disease: an early study. Mov Disord 2000 Jan; 15 (1): 65-70
72. Gray A, McNamar I, Aziz T, et al. Quality of life outcomes following surgical treatment of Parkinson's disease. Mov Distion ord 2002; 17 (1): 68-75
73. Scott R, Gregory R, Hines N, et al. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease: a consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain 1998 Apr; 121: 659-75
74. Drapier S, Raoul S, Drapier D, et al. Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson's disease. J Neurol 2005; 252: 583-8
75. Siderowf A, Jaggi JL, Xie SX, et al. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. Mov Disord, Epub 2006 Feb 6
76. Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord 2002 Mar; 17 (2): 372-7
77. Vingerhoets G, Lannoo E, Van der Linden C, et al. Changes in quality of life following unilateral pallidal stimulation in Parkinson's disease. J Psychosom Res 1999; 46 (3): 247-55
78. Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of health-care utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002 Jun; 249 (6): 759-66
79. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004 Jan 27; 62 (2): 201-7
80. Erola T, Karinen P, Heikkinen E, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in parkinsonian patients. Parkinsonism Relat Disord 2005; 11: 89-94
81. Daniele A, Albanese A, Contarino MF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003 Feb; 74 (2): 175-82
82. Lagrange E, Krack P, Moro E, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002 Dec 24; 59 (12): 1976-8
83. Patel NK, Plaha P, O'Sullivan K, et al. MRI directed bilateral stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003 Dec; 74 (12): 1631-7
84. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004; 61: 412-20
85. Croyle KL, Tr̈oster AI, Fields JA, et al. Presurgical coping, depression, and quality of life in persons with Parkinson's disease. J Clin Psychol Med Settings 2003 Jun; 10 (2): 101-7
86. Hariz GM, Lindberg M, Hariz MI, et al. Gender differences in disability and health-related quality of life in patients with Parkinson's disease treated with stereotactic surgery. Acta Neurol Scand 2003; 108: 28-37
87. Kuehler A, Henrich G, Schroeder U, et al. A novel quality of life instrument for deep brain stimulation in movement disorders. J Neurol Neurosurg Psychiatry 2003; 74: 1023-30
88. Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. Am J Med 1994 Nov; 97 (5): 429-35
89. Shimbo T, Goto M, Morimoto T, et al. Association between patient education and health-related quality of life in patients with Parkinson's disease. Qual Life Res 2004; 13 (1): 81-9
90. Sunvisson H, Ekman SL, Hagberg H, et al. An education programme for individuals with Parkinson's disease. Scand J Caring Sci 2001; 15 (4): 311-7
91. Ward CD, Turpin G, Dewey ME, et al. Education for people with progressive neurological conditions can have negative effects: evidence from a randomized controlled trial. Clin Rehabil 2004 Nov; 18 (7): 717-25
92. Mercer BS. Randomized study of the efficacy of the PROPATH program for patients with Parkinson disease. Arch Neurol 1996 Sep; 53 (9): 881-4
93. Cubo E, Rojo A, Ramos S, et al. The importance of educational and psychological factors in Parkinson's disease quality of life. Eur J Neurol 2002; 9: 589-93
94. Rocca WA, Anderson DW, Meneghini F, et al. Occupation, education, and Parkinson's disease: a case-control study in an Italian population. Mov Disord 1996 Mar; 11 (2): 201-6
95. Pai MC, Chan SH. Education and cognitive decline in Parkinson's disease: a study of 102 patients. Acta Neurol Scand 2001 Apr; 103 (4): 243-7
96. Martinez-Martin P, Benito-Leon J, Alonso F, et al. Quality of life of caregivers in Parkinson's disease. Qual Life Res 2005 Mar; 14 (2): 463-72
97. Calder SA, Ebmeier KP, Stewart L, et al. The prediction of stress in carers: the role of behaviour, reported self-care and dementia in patients with idiopathic Parkinson's disease. Int J Geriatr Psychiatr 1991 Oct; 6 (10): 737-42
98. Glozman JM, Bicheva KG, Fedorova NV. Scale of Quality of Life of Caregivers (SQLC). J Neurol 1998 May; 245: S39-41
99. Dixon S, Walker M, Salek S. Incorporating carer effects into economic evaluation. Pharmacoeconomics 2006; 24 (1): 43-53
100. McRae C, Sherry P, Roper K. Stress and family functioning among caregivers of persons with Parkinson's disease. Parkinsonism Relat Disord 1999; 5: 69-75
101. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Mov Disord 1998 Jan; 13 (1): 20-8
102. Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9: 163-8
103. McGuigan S. Compendium of health statistics. London: Office of Health Economics, 1997
104. Prevalence of treated hypertension per 1000 patients, by age, sex and calendar year: 1994-98. Newport: Office for National Statistics [online]. Available from URL: http://www.statistics.gov.uk/STATBASE/xsdataset.asp?More= Y&vlnk=2337&All=Y&B2.x=60&B2.y=12 [Accessed 2006 Sep 18]
105. Prevalence of treated asthma per 1000 patients, by age, sex and calendar year: 1994-98. Newport: Office for National Statistics [online]. Available from URL: http://www.statistics.gov.uk/STATBASE/xsdataset.asp?More=Y&vlnk= 2345&All=Y&B2.x=149&B2.y=11 [Accessed 2006 Sep 18]
106. Frequently asked questions (FAQs): who gets Parkinson's? London: Parkinson's Disease Society, 2006 [online]. Available from URL: http://www.parkinsons.org.uk/Templates/Internal.asp?NodeID=89606 [Accessed 2006 Apr 10]
107. Schiefe RT, Schumock GT, Burstein A, et al. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000; 57: 953-62
108. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003 Oct; 18 (10): 1139-45
109. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998 Sep; 14 (3): 299-312
110. Shimbo T, Hira K, Takemura M, et al. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001; 19 (8): 875-86
111. Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson's disease. Mov Disord 1998 Mar; 13 (2): 249-54
112. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000; 15 (3): 439-45
113. Charles PD, Padaliya BB, Newman WJ, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 2004 Dec; 10 (8): 475-9
114. McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease. Mov Disord 2003 Sep; 18 (9): 993-9
115. Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005 Feb; 252 (2): 218-23
116. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001 Aug 28; 57 (4): 663-71
117. Green AL, Joint C, Sethi H, et al. Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease. J Clin Neurosci 2004 Nov; 11 (8): 829-34
118. Palmer CS, Nuijten MJC, Schmier JK, et al. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002; 20 (9): 614-28
119. Nuijten MJC, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001; 4 (4): 316-28
120. Hoerger TJ, Bala MV, Rowland C, et al. Cost-effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998; 14 (5): 541-57
121. Noyes K, Dick AW, Holloway RG. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness. Pharmacoeconomics 2005; 23 (12): 1257-70
122. Hempel AG, Wagner ML, Maaty MA, et al. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998 Sep; 32 (9): 878-83
123. Smala AM, Spottke EA, Machat O, et al. Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord 2003; 18 (8): 898-905
124. Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Pharmacoeconomics 2003; 21 (2): 115-27
125. Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001; 4 (4): 308-15
126. Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005 Jul; 21 (7): 1005-14